A new frontier in the treatment of cancer: NK-1 receptor antagonists.
about
Biological and Pharmacological Aspects of the NK1-ReceptorTumor interactions with soluble factors and the nervous system.Involvement of substance P and the NK-1 receptor in human pathology.The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.Truncated neurokinin-1 receptor is an ubiquitous antitumor target in hepatoblastoma, and its expression is independent of tumor biology and stageAn indirect role for oncomir-519b in the expression of truncated neurokinin-1 in breast cancer cells.Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells.High expression of substance P and its receptor neurokinin-1 receptor in colorectal cancer is associated with tumor progression and prognosis.Involvement of substance P and the NK-1 receptor in pancreatic cancer.NK-1 as a melanoma target.NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.Molecular imaging probes derived from natural peptides.Effect of truncated neurokinin-1 receptor expression changes on the interaction between human breast cancer and bone marrow-derived mesenchymal stem cells.Substance P Regulation in Epilepsy.The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer ChemoresistanceDifference in expression of two neurokinin-1 receptors in adenoma and carcinoma from patients that underwent radical surgery for colorectal carcinoma.The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines.The role of substance P in epilepsy and seizure disorders.Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence.Immunolocalization of substance P and NK-1 receptor in vascular anomalies.Expression of proliferative markers in ameloblastomas and malignant odontogenic tumors.Neuroendocrine Factors and Head and Neck Squamous Cell Carcinoma: An Affair to Remember.The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer
P2860
Q26784074-F3755D0D-446E-484D-847B-815F532FAFA6Q34142510-9F1CC599-262E-42DC-8F37-383D0EF8DB0DQ34413850-349690AB-75FE-4AA0-95A2-BEA2D89A0FC6Q34475975-A14FEDAB-998A-4B94-B45B-B9C898F2CEDEQ36502347-3450EA59-CE54-4BFB-86D3-2D903F7DAB0DQ36819288-AECFD656-4EA0-426F-8FD5-A19FB53308D1Q37004651-4274189F-777A-48DB-B753-B90477304E22Q37021243-415671EF-AC2E-4008-8EBE-1DC2B9B6EA33Q37617971-E986B380-89DB-4DF3-923E-B6951D02085FQ37876914-55611164-0E39-49B3-B7F0-7D761A330E65Q38018635-3BFA485D-DCE9-47EA-AE21-0173E1DC3F74Q38748846-91A475B5-7665-4289-A422-6432A0A288BEQ38965246-540E3EBB-E103-48F6-82F4-00C7851272C4Q39285392-AD04907C-B6FC-438C-9CA4-A00C3AE86B85Q39625473-48498857-0FA9-4AD3-B15D-5B7392FDDAB9Q40753692-189A0A8C-C2C1-4146-BB02-03B4FB2B487BQ41618379-C5FFA65F-6DFA-4B78-8F88-67584FB34E2FQ42875830-660A19C0-9F26-4579-8E6A-AE5D09AF53D0Q44221614-B83F6F4E-7D67-4076-972E-AAC67E1B1FD7Q48371016-348F2445-7034-45FD-B536-DCE24B870070Q51252675-2961DD05-5D18-4223-842E-FEE98BF0C332Q53264577-B4672E5D-E8DC-4F73-BE39-74F57E1934A9Q55020898-76106E3D-1DA7-4F33-A466-2033EB1CFA7FQ58914868-05EA1C91-9B47-4BFE-8205-A0CA9AA437DA
P2860
A new frontier in the treatment of cancer: NK-1 receptor antagonists.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
A new frontier in the treatment of cancer: NK-1 receptor antagonists.
@ast
A new frontier in the treatment of cancer: NK-1 receptor antagonists.
@en
A new frontier in the treatment of cancer: NK-1 receptor antagonists.
@nl
type
label
A new frontier in the treatment of cancer: NK-1 receptor antagonists.
@ast
A new frontier in the treatment of cancer: NK-1 receptor antagonists.
@en
A new frontier in the treatment of cancer: NK-1 receptor antagonists.
@nl
prefLabel
A new frontier in the treatment of cancer: NK-1 receptor antagonists.
@ast
A new frontier in the treatment of cancer: NK-1 receptor antagonists.
@en
A new frontier in the treatment of cancer: NK-1 receptor antagonists.
@nl
P2093
P1476
A new frontier in the treatment of cancer: NK-1 receptor antagonists.
@en
P2093
P304
P356
10.2174/092986710790416308
P577
2010-01-01T00:00:00Z